Camber Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Camber Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,715	Closed	-$899K	–	51
2015 Q3	$899K	Sell	1,715 -266	-13%	-$406K	0.08%	43
2015 Q2	$4.35M	Hold	1,981	–	–	0.3%	41
2015 Q1	$4.63M	Hold	1,981	–	–	0.33%	34
2014 Q4	$4.1M	Hold	1,981	–	–	0.27%	38
2014 Q3	$3.95M	Hold	1,981	–	–	0.37%	36
2014 Q2	$7.04M	Hold	1,981	–	–	0.46%	36
2014 Q1	$7.41M	Buy	1,981 +1,746	+743%	+$6.46M	0.58%	34
2013 Q4	$768K	Buy	+235	New	+$926K	0.07%	36

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCM

Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Camber Capital Management's GYRE Position: Q4 2015 in Review

Camber Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2015, closing a stake of 1,715 shares — an estimated $899K sold.

Camber Capital Management first reported a position in GYRE in Q4 2013 and held it in 8 quarters. The position peaked at $7.41M in Q1 2014. 35 funds tracked by Wall St. Rank hold GYRE as of Q4 2015.

Camber Capital Management reported no remaining Gyre Therapeutics position as of Q4 2015 after selling out during the quarter.
Camber Capital Management sold 1,715 Gyre Therapeutics shares in Q4 2015, an estimated $899K.
Camber Capital Management first reported a position in Gyre Therapeutics in Q4 2013 and held it in 8 quarters.
Camber Capital Management's Gyre Therapeutics position peaked at $7.41M in Q1 2014.
35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2015.

Based on Camber Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.